Zenith will be presenting at the AACR meeting in New Orleans on Monday April 18th. This presentation comes the day before Zenith's presentation at the Epigenetics Inhibitor Discovery meeting in San Diego April 19-21, and shortly after that is the Epigenetics: Cancer and Beyond meeting in New York April 28th.

Here is the AACR info (full abstract not posted until April 15).

Abstract Number:LB-207

Presentation Title: Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC)

Presentation Time:Monday, Apr 18, 2016, 1:00 PM - 5:00 PM [my note: their abstract will likely be presented as part of a poster session. It is unclear if there is an oral presentation]

Location:Section 12

Author Block:Sarah Attwell1, Ravi Jahagirdar1, Karen Norek1, Cyrus Calosing1, Laura Tsujikawa1, Olesya A. Kharenko1, Reena G. Patel1, Emily M. Gesner1, Eva Corey2, Holly M. Nguyen2, Sanjay Lakhotia1, Henrik C. Hansen1, Eric Campeau1. 1Zenith Epigenetics, Calgary, AB, Canada; 2University of Washington, Seattle, WA

Session Title:Late-Breaking Research: Experimental and Molecular Therapeutics 2

Session Type:Late-Breaking Poster Session